The effect of tamoxifen on lipid and haemostatic predictors of ischaemic heart disease

Journal of Drug Development and Clinical Practice

Volumn 8, Issue 1, 1996, Pages 19-24

  Mikhailidis, D P ^a   Spyropoulos, K A ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Ischaemic heart disease; Lipids; Risk factors; Tamoxifen

Indexed keywords

ANTIESTROGEN; CHOLESTEROL; FIBRINOGEN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TAMOXIFEN; TRIACYLGLYCEROL;

ADULT; AGED; ANTIOXIDANT ACTIVITY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FIBRINOGEN BLOOD LEVEL; HEART INFARCTION; HEART PROTECTION; HEMOSTASIS; HUMAN; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; META ANALYSIS; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0029871664     PISSN: 13579215     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Powles TJ, Hickish TF, Makris A, et al. J Clin Oncol 1995;13:547-552.
2. McDonald CC, Stewart HJ for the Scottish Adjuvant Tamoxifen Trial. Br Med J 1991;303:435-437.
3. Chlebowski RT, Butler J, Nelson A, Lillington L. Cancer 1993;72:1032-1037.
4. Early Breast Cancer Trialists Collaborative Group. Lancet 1992;339:1-15;71-85.
5. Powles TJ, Jones AL, Ashley SE, et al. Breast Cancer Res Treat 1994;31:73-82.
6. O'Brien M, Powles TJ. Drug Saf 1994;10:1-4.
7. Nayfield SG, Karp JE, Ford LG, et al. JNCI 1991;83:1450-1459.
8. Jordan VC. Br Med J 1993;307:1371-1372.
9. Bush TL, Helzlsouer KJ. Epidemiol Rev 1993;15:233-243.
10. Matthews KA, Meilahn E, Kuller LH, et al. N Engl J Med 1989;321:641-646.
11. Stampfer MJ, Colditz GA. Prev Med 1991;20:47-63.
12. Dewar JA, Horobin JM, Preece PE, et al. Br Med J 1992;305:225-226.
13. Love RR, Wiebe DA, Newcomb PA, et al. Ann Intern Med 1991;115:860-864.
14. Schapira DV, Kumar NB, Lyman GH. Breast Cancer Res Treat 1990;17:3-7.
15. Ingram D. Aust NZ J Surg 1990;60:673-675.
16. Bagdade JD, Wolter J, Subbaiah PV, Ryan W J Clin Endocrinol Metab 1990;70:1132-1135.
17. Bertelli G, Pronzato P, Amoroso D, et al. Breast Cancer Res Treat 1988;12:307-310.
18. Bruning PF, Bonfre JMG, Man AAM, et al. Br J Cancer 1988;58:497-499.
19. Dnistrian AM, Schwartz MK, Greenberg EJ, et al. Clin Chim Acta 1993;223:43-52.
20. Powles TJ, Tillyer CR, Jones AL, et al. Eur J Cancer 1990;26:680-684.
21. Caleffi M, Fentiman IS, Clark GM, et al. J Endocrinol 1988;119:335-339.
22. Rospond RM, Baker L, Rabbass C, Mailliard JA [abstract]. Pharmacotherapy 1994;14:361.
23. Scanu AM, Scandiani L. Adv Intern Med 1991;36:249-270.
24. Shewmon DA, Stock JL, Abusamra LC, et al. Metabolism 1994;43:531-532.
25. Elisaf M, Bairaktari H, Nikolaidis C, et al [abstract]. Atherosclerosis 1995;11:S111.
26. Grainger DJ, Kirschenlohr HL, Metcalfe JC, et al. Science 1993;260:1655-1658.
27. Seed M, Crook D. Curr Opin Lipidol 1994;5:48-58.
28. Ernst E. Br Med J 1991;303:596-597.
29. Cuzick J, Alleln D, Baum M, et al. Eur J Cancer 1993;29A:15-21.
30. Pemberton KD, Melissari E, Kakkar VV. Blood Coagul Fibrinolysis 1993;4:935-942.
31. Fukutomi T. Jpn J Cancer Res 1993;84:455-461.
32. Love RR, Surawicz TS, Williams EC. Arch Intern Med 1992;152:317-320.
33. Wiseman H, Quinn P, Halliwell B. FEBS Lett 1993;330:53-56.
34. Wiseman H, Paganga G, Rice-Evans C, Halliwell B. Biochem J 1993;292:635-638.
35. Ahotupa M, Hirsimaeki P, Paerssinen R, Maentylae E. Carcinogenesis 1994;15:863-868.
36. Schwertner HA, Jackson WC, Tolan G. Clin Chem 1994;40:18-24.
37. Breimer LH, Spyropoulos KA, Winder AF, et al. Clin Chem 1994;40:1987-1988.
38. Rutqvist LE, Mattsson A. JNCI 1993;85:1398-1406.
39. McDonald CC, Alexander FE, Whyte BW, et al. for the Scottish Cancer Trials Breast Group. Br Med J 1995;311:977-980.
40. Bissett D, Davis JA, George WD. Lancet 1994;344:1244.
41. Neven P, De Muylder X, Van Belle Y, et al. Br Med J 1994;309:1313-1314.
42. Van Leeuwen FE, Benraadt J, Coebergh JWW, et al. Lancet 1994;343:448-452.